- Home
- RVPHW vs METCB Comparison
RVPHW vs METCB Comparison
Compare RVPHW & METCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPHW
- METCB
- Stock Information
- Founded
- RVPHW 2018
- METCB 2015
- Country
- RVPHW United States
- METCB United States
- Employees
- RVPHW 15
- METCB N/A
- Industry
- RVPHW Biotechnology: Pharmaceutical Preparations
- METCB Coal Mining
- Sector
- RVPHW Health Care
- METCB Energy
- Exchange
- RVPHW Nasdaq
- METCB Nasdaq
- Market Cap
- RVPHW N/A
- METCB N/A
- IPO Year
- RVPHW N/A
- METCB N/A
- Fundamental
- Price
- RVPHW $0.03
- METCB $7.25
- Analyst Decision
- RVPHW
- METCB Strong Buy
- Analyst Count
- RVPHW 0
- METCB 3
- Target Price
- RVPHW N/A
- METCB $17.00
- AVG Volume (30 Days)
- RVPHW 22.4K
- METCB 71.5K
- Earning Date
- RVPHW 03-14-2025
- METCB 05-07-2025
- Dividend Yield
- RVPHW N/A
- METCB 12.35%
- EPS Growth
- RVPHW N/A
- METCB N/A
- EPS
- RVPHW N/A
- METCB 0.21
- Revenue
- RVPHW N/A
- METCB $666,295,000.00
- Revenue This Year
- RVPHW N/A
- METCB $12.66
- Revenue Next Year
- RVPHW N/A
- METCB $17.56
- P/E Ratio
- RVPHW N/A
- METCB $39.95
- Revenue Growth
- RVPHW N/A
- METCB N/A
- 52 Week Low
- RVPHW $0.13
- METCB $6.85
- 52 Week High
- RVPHW $0.15
- METCB $12.43
- Technical
- Relative Strength Index (RSI)
- RVPHW N/A
- METCB 34.58
- Support Level
- RVPHW N/A
- METCB $6.85
- Resistance Level
- RVPHW N/A
- METCB $8.17
- Average True Range (ATR)
- RVPHW 0.00
- METCB 0.47
- MACD
- RVPHW 0.00
- METCB -0.09
- Stochastic Oscillator
- RVPHW 0.00
- METCB 19.40
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.